Skip to main content

Table 1 Demographic and clinical characteristics in the fracture risk analysis population by ATI and fracture status

From: The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients

Parameter

 < 18 years ATI cohort

18 to < 50 years ATI cohort

>= 50 years ATI cohort

Patients with fracture

Patients without fracture

Patients with fracture

Patients without fracture

Patients with fracture

Patients without fracture

Number of patients, n

 

33

623

167

1318

88

419

Sex, n (%)

 Male

14 (42.4)

297 (47.7)

72 (43.1)

569 (43.2)

30 (34.1)

241 (57.5)

 Female

19 (57.6)

326 (52.3)

95 (56.9)

749 (56.8)

58 (65.9)

178 (42.5)

Age at GD1 diagnosis, years

 Mean (SD)

8.3 (4.64)

7.0 (4.33)

20.5 (13.44)

23.2 (12.65)

45.7 (18.26)

38.8 (20.45)

 Median (25th, 75th)

6.9 (4.6, 11.8)

6.1 (3.6, 10.0)

20.8 (7.5, 29.3)

23.5 (12.8, 32.6)

50.1 (32.9, 58.3)

39.8 (23.2, 55.3)

 Range

2.9, 17.6

0.0, 17.4

0.0, 49.3

0.0, 49.7

0.5, 81.8

2.3, 78.9

Age at imiglucerase initiation, years

 Mean (SD)

12.0 (4.61)

10.0 (4.48)

36.6 (8.22)

33.8 (9.03)

60.5 (8.00)

60.9 (8.32)

 Median (25th, 75th)

14.1 (8.3, 15.2)

10.2 (6.1, 13.8)

37.5 (30.3, 43.7)

33.8 (26.5, 41.4)

59.0 (53.8, 65.6)

59.3 (54.4, 65.7)

 Range

3.1, 17.9

0.2, 18.0

18.3, 49.9

18.0, 50.0

50.0, 84.1

50.2, 84.2

Time interval between diagnosis and imiglucerase initiation, years

 Mean (SD)

3.7 (4.36)

2.9 (3.79)

16.1 (12.09)

10.6 (11.02)

14.9 (15.95)

22.1 (18.59)

 Median (25th, 75th)

0.9 (0.3, 7.7)

1.0 (0.3, 4.6)

17.5 (2.9, 25.0)

6.8 (0.7, 18.0)

8.9 (0.8, 26.7)

18.4 (1.4, 39.1)

 Range

0.1, 12.9

0.0, 16.6

0.0, 44.0

0.0, 46.5

0.0, 61.4

0.0, 60.6

Genotype, n (%)

 N370S/N370S

6 (18.2)

65 (10.4)

35 (21.0)

309 (23.4)

43 (48.9)

166 (39.6)

 All other genotypes

24 (72.7)

481 (77.2)

116 (69.4)

775 (58.8)

34 (38.6)

179 (42.7)

 Unknown genotype

3 (9.1)

77 (12.4)

16 (9.6)

234 (17.8)

11 (12.5)

74 (17.7)

Splenectomized prior to or on treatment initiation date, n (%)

 No

27 (81.8)

567 (91.0)

88 (52.7)

942 (71.5)

56 (63.6)

299 (71.4)

 Yes

6 (18.2)

56 (9.0)

79 (47.3)

376 (28.5)

32 (36.4)

120 (28.6)

Age at splenectomy, years

 n

6

56

79

376

32

120

 Mean (SD)

8.7 (4.84)

7.7 (3.97)

17.5 (11.27)

19.4 (10.74)

27.2 (13.78)

36.6 (16.62)

 Median (25th, 75th)

8.3 (3.8, 12.6)

7.5 (4.3, 10.1)

14.1 (8.0, 25.3)

18.5 (10.4, 26.5)

27.2 (14.2, 37.1)

37.8 (23.0, 50.1)

 Range

3.7, 15.6

2.1, 17.3

1.7, 45.0

1.5, 48.8

5.0, 57.1

4.5, 72.9

Bone crisis reported prior to or on treatment initiation date, n (%)

 No

30 (90.9)

555 (89.1)

134 (80.2)

1201 (91.1)

77 (87.5)

398 (95.0)

 Yes

3 (9.1)

68 (10.9)

33 (19.8)

117 (8.9)

11 (12.5)

21 (5.0)

  1. ATI = Age at treatment initiation; GD1 = Gaucher disease type 1
  2. *Excludes patients from total study sample with first fracture prior to treatment initiation, first fracture prior to age 18, and patients whose follow-up did not extend past age 18 years